Bioservices Market

By Industry;

Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research & Manufacturing Services (CRAMS)

By Technology;

Fermentation, Tissue Regeneration, PCR Technology, Nanobiotechnology, Chromatography, DNA Sequencing, Cell Based Assay, and Others

By Research;

Pharmaceutical, Biotechnological, Academic & Clinical Trial, and Healthcare Sectors

By Application;

Donor Recruitment, Tissue Collection, Cell Processing & Isolation, and Research & Development

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn606480384 Published Date: August, 2025 Updated Date: September, 2025

Bioservices Market Overview

Bioservices Market (USD Million)

Bioservices Market was valued at USD 160535.04 million in the year 2024. The size of this market is expected to increase to USD 257784.20 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Bioservices Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 160535.04 Million
Market Size (2031)USD 257784.20 Million
Market ConcentrationMedium
Report Pages342
160535.04
2024
257784.20
2031

Major Players

  • Charles River Laboratories International, Inc.
  • Eurofins Scientific
  • Covance Inc. (LabCorp)
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Parexel International Corporation
  • ICON plc
  • Syneos Health Inc.
  • WuXi AppTec
  • PRA Health Sciences

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Bioservices Market

Fragmented - Highly competitive market without dominant players


The Bioservices Market is growing rapidly as companies in the life sciences sector increasingly outsource essential activities. More than 45% of biopharmaceutical firms now depend on bioservices for clinical trials, drug development, and genomic solutions. This reliance is driven by the need for efficiency, cost reduction, and specialized knowledge, making bioservices vital for accelerating healthcare progress.

Technological Advancements Boosting Adoption
The rise of next-generation sequencing, bioinformatics, and advanced cell line development has enhanced the adoption of bioservices. Nearly 50% of research institutions now use these services to streamline R&D processes. By enabling faster analysis and higher productivity, bioservices are reshaping the research landscape and ensuring more effective biomedical outcomes.

Growing Outsourcing Practices
With drug development becoming increasingly complex, over 55% of pharmaceutical companies have shifted towards outsourcing parts of their workflows. Bioservice providers offer advanced infrastructure and expertise, reducing costs while accelerating innovation. This outsourcing model also allows organizations to focus resources on their primary strengths, creating stronger pipelines for therapeutic breakthroughs.

Quality and Compliance as Core Priorities
Maintaining strict quality standards has emerged as a critical factor for bioservices. Around 60% of providers prioritize compliance with global regulatory frameworks, ensuring consistency and reliability in outcomes. This focus strengthens confidence among pharmaceutical and biotech companies, making bioservices a trusted partner in regulated research and clinical environments.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Industry
    2. Market Snapshot, By Technology
    3. Market Snapshot, By Research
    4. Market Snapshot, By Application
    5. Market Snapshot, By Region
  4. Bioservices Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increased demand growth
        2. Technological advancements
        3. Outsourcing trend
        4. Growing pharmaceutical industry
        5. Research and development
      2. Restraints
        1. Regulatory challenges
        2. High competition levels
        3. Cost constraints
        4. Data security concerns
        5. Limited scalability
      3. Opportunities
        1. Emerging markets expansion
        2. Personalized medicine demand
        3. Contract research outsourcing
        4. Collaborations and partnerships
        5. Digitalization advantages
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Bioservices Market, By Industry, 2021 - 2031 (USD Million)
      1. Clinical Research Organizations (CROs)
      2. Contract Manufacturers Organizations(CMOs)
      3. Contract Research & Manufacturing Services (CRAMS)
    2. Bioservices Market, By Technology, 2021 - 2031 (USD Million)

      1. Fermentation

      2. Tissue Regeneration

      3. PCR Technology

      4. Nanobiotechnology

      5. Chromatography

      6. DNA Sequencing

      7. Cell Based Assay

      8. Others

    3. Bioservices Market, By Research, 2021 - 2031 (USD Million)
      1. Pharmaceutical
      2. Biotechnological Academic & Clinical Trial
      3. Healthcare Sectors
    4. Bioservices Market, By Application, 2021 - 2031 (USD Million)
      1. Donor Recruitment
      2. Tissue Collection
      3. Cell Processing & Isolation
      4. Research & Development
    5. Bioservices Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Charles River Laboratories International, Inc.
      2. Eurofins Scientific
      3. Covance Inc. (LabCorp)
      4. IQVIA Holdings Inc.
      5. Laboratory Corporation of America Holdings (LabCorp)
      6. Parexel International Corporation
      7. ICON plc
      8. Syneos Health Inc.
      9. WuXi AppTec
      10. PRA Health Sciences
  7. Analyst Views
  8. Future Outlook of the Market